Home » Stocks » TECH

Bio-Techne Corp (TECH)

Stock Price: $474.40 USD 5.22 (1.11%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 18.45B
Revenue (ttm) 847.84M
Net Income (ttm) 184.30M
Shares Out 38.86M
EPS (ttm) 4.59
PE Ratio 103.29
Forward PE 64.10
Dividend $1.28
Dividend Yield 0.27%
Trading Day July 23
Last Price $474.40
Previous Close $469.18
Change ($) 5.22
Change (%) 1.11%
Day's Open 470.56
Day's Range 470.56 - 479.00
Day's Volume 117,431
52-Week Range 228.05 - 479.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

ALXN vs. TECH: Which Stock Is the Better Value Option?

Other stocks mentioned: ALXN
3 days ago - Zacks Investment Research

Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?

6 days ago - Zacks Investment Research

MINNEAPOLIS, July 13, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Thursday, August 5, 2021, at 8:00 a.m. CDT to ...

1 week ago - PRNewsWire

MINNEAPOLIS, June 28, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the opening of its new Ireland facility located in Dublin. This new facility reflects Bio-Techne's commitm...

3 weeks ago - PRNewsWire

As of Friday, GuruFocus' “High Quality, Low CapEx” model portfolio has returned approximately 15.69% in the year to date, outperforming the Standard & Poor's 500 index benchmark's return of approximatel...

Other stocks mentioned: FTNT, GOOG, GOOGL, NVDA, ODFL
4 weeks ago - GuruFocus

MINNEAPOLIS and CAMBRIDGE, Mass., June 24, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Catamaran Bio today announced an expansion of their collaboration for the development of cell en...

1 month ago - PRNewsWire

CAMBRIDGE, Mass. & MINNEAPOLIS--(BUSINESS WIRE)--Catamaran Bio and Bio-Techne Announce Expanded Collaboration for CAR NK Cell Manufacturing Technologies

1 month ago - Business Wire

MINNEAPOLIS and LONDON, June 10, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leader in developing innovative tools and technologies for cell and gene therapy research and manufacturing...

1 month ago - PRNewsWire

MINNEAPOLIS, June 8, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it is joining the Cell and Gene Therapy Catapult process analytical technology (PAT) consortium, which inc...

1 month ago - PRNewsWire

Benjamin Graham, the father of value investing, suggested screening the market for stocks that have a current ratio of more than 2 plus more working capital than long-term debt.

Other stocks mentioned: CREE, ZLAB
1 month ago - GuruFocus

Techne (TECH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 month ago - Zacks Investment Research

MINNEAPOLIS, May 19, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcar...

2 months ago - PRNewsWire

MINNEAPOLIS, May 18, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a collaboration with Narayana Nethralaya to develop a diagnostic solution for ophthalmology disorders on i...

2 months ago - PRNewsWire

MINNEAPOLIS, May 10, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Asuragen, a Bio-Techne brand, and scientific collaborators have published the results of a multisite e...

2 months ago - PRNewsWire

Techne (TECH) delivered earnings and revenue surprises of 19.33% and 7.84%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

MINNEAPOLIS, May 6, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended March 31, 2021...

2 months ago - PRNewsWire

MINNEAPOLIS, May 6, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ended March 31, 2021. Third Quarter FY2021 Snapshot Third quarter...

2 months ago - PRNewsWire

NEW YORK, May 4, 2021 /PRNewswire/ -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE: RENX) (NASDAQ: RNLX), announced today that COVID-SeroKlir, its...

Other stocks mentioned: RNLX
2 months ago - PRNewsWire

BOSTON & MINNEAPOLIS--(BUSINESS WIRE)--908 Devices (NASDAQ: MASS) and Bio-Techne Corporation (NASDAQ: TECH) today announced a joint collaboration to develop an extended workflow solution for protein cha...

Other stocks mentioned: MASS
2 months ago - Business Wire

MINNEAPOLIS and BOSTON, May 4, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and 908 Devices (NASDAQ: MASS) today announced a joint collaboration to develop an extended workflow solution fo...

Other stocks mentioned: MASS
2 months ago - PRNewsWire

Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Bio-Techne is in a potential buy area as it gets ready to report earnings on May 6. The stock is about 4% above a 415.09 buy point from a second-stage.

2 months ago - Investors Business Daily

MINNEAPOLIS, April 27, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the expansion of the Advanced Cell Diagnostics (ACD), a Bio-Techne brand, RNAscope™ technology with relea...

2 months ago - PRNewsWire

MINNEAPOLIS, April 15, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Advanced Cell Diagnostics (ACD), a Bio-Techne brand, completed an extensive rebranding effort in re...

3 months ago - PRNewsWire

MINNEAPOLIS, April 14, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a license agreement for use of a proprietary Bio-Techne antibody by Xencor, Inc., a clinical-stage bioph...

3 months ago - PRNewsWire

The IBD SmartSelect Composite Rating for Bio-Techne rose from 94 to 96 Wednesday. The post Bio-Techne Gets IBD Stock Rating Upgrade appeared first on Investor's Business Daily.

3 months ago - Investors Business Daily

QGEN vs. TECH: Which Stock Is the Better Value Option?

Other stocks mentioned: QGEN
3 months ago - Zacks Investment Research

MINNEAPOLIS, April 8, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that ProteinSimple, a Bio-Techne brand, released Abby, its next generation chemiluminescence system that a...

3 months ago - PRNewsWire

MINNEAPOLIS, April 6, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed the acquisition of Asuragen, Inc.  The transaction included initial consideration of $21...

3 months ago - PRNewsWire

MINNEAPOLIS, April 6, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Thursday, May 6, 2021, at 8:00 a.m. CDT to rev...

3 months ago - PRNewsWire

MINNEAPOLIS, March 29, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the release of Cultrex™ UltiMatrix™ Reduced Growth Factor Basement Membrane Extract (RGF BME), an extrac...

3 months ago - PRNewsWire

MINNEAPOLIS, March 26, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that its R&D Systems and Novus brands have been named winners of the CiteAb COVID-19 Innovation Award.  ...

3 months ago - PRNewsWire

MINNEAPOLIS, March 23, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has completed its clinical validation of an in vitro diagno...

4 months ago - PRNewsWire

MINNEAPOLIS, March 15, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnost...

4 months ago - PRNewsWire

NEW YORK, March 10, 2021 /PRNewswire/ -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE: RENX / NASDAQ: RNLX), announced today it has been named to ...

4 months ago - PRNewsWire

MINNEAPOLIS, March 8, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has published preliminary data on its kidney transplant rej...

4 months ago - PRNewsWire

Bio-Techne Corp (NASDAQ: TECH) has agreed to acquire Asuragen Inc, a provider of genetic carrier screening and oncology testing kits. The deal value includes an initial consideration of $215 million in ...

4 months ago - Benzinga

MINNEAPOLIS and AUSTIN, Texas, March 3, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and ...

4 months ago - PRNewsWire

MINNEAPOLIS, March 1, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Humana has awarded a contract effective April 1, 2021 to its Exosome Diagnostics laboratory, covering...

4 months ago - PRNewsWire

MINNEAPOLIS, Feb. 23, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the signing of a license agreement with Luminary Therapeutics for the use of TcBuster™ for the manufactur...

5 months ago - PRNewsWire

MINNEAPOLIS, Feb. 11, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has recently published a paper entitled Exosome-based Liquid...

5 months ago - PRNewsWire

NEW YORK, Feb. 10, 2021 /PRNewswire/ -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE:RENX / NASDAQ: RNLX), and manufacturing partner Bio-Techne Co...

5 months ago - PRNewsWire

MINNEAPOLIS, Feb. 10, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 2021 SVB Leerink Global He...

5 months ago - PRNewsWire

NEW YORK, Feb. 8, 2021 /PRNewswire/ -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE:RENX / NASDAQ: RNLX), and manufacturing partner Bio-Techne Cor...

5 months ago - PRNewsWire

MINNEAPOLIS, Feb. 3, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that ProteinSimple, a Bio-Techne brand, has expanded its Simple PlexTM immunoassay cartridge portfolio to ...

5 months ago - PRNewsWire

Bio-Techne saw its IBD SmartSelect Composite Rating rise to 96 Wednesday, up from 92 the day before. The post Composite Rating For Bio-Techne Jumps To 96 appeared first on Investor's Business Daily.

5 months ago - Investors Business Daily

Bio-Techne Corporation (TECH) CEO Charles Kummeth on Q2 2021 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Techne (TECH) delivered earnings and revenue surprises of 19.12% and 9.11%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Shares of Bio-Techne (NASDAQ:TECH) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share increased 50.00% year over year to $1.62, which beat the estimate of $1...

5 months ago - Benzinga

MINNEAPOLIS, Feb. 2, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ended December 31, 2020. Second Quarter FY2021 Snapshot Second ...

5 months ago - PRNewsWire

About TECH

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates in two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and T-Cell activation technologies. This segment also provid... [Read more...]

Industry
Biotechnology
IPO Date
Feb 9, 1989
CEO
Charles Kummeth
Employees
2,300
Stock Exchange
NASDAQ
Ticker Symbol
TECH
Full Company Profile

Financial Performance

In 2020, Bio-Techne's revenue was $738.69 million, an increase of 3.46% compared to the previous year's $714.01 million. Earnings were $229.30 million, an increase of 138.67%.

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for Bio-Techne stock is "Buy." The 12-month stock price forecast is 457.22, which is a decrease of -3.62% from the latest price.

Price Target
$457.22
(-3.62% downside)
Analyst Consensus: Buy